Federal Register / Vol. 87, No. 19 / Friday, January 28, 2022 / Notices 4629 

nbsb. Members of the public may 

provide written comments or submit 

questions for consideration by the NBSB 

at any time via email to NBSB@hhs.gov. 

Additionally, the NBSB invites 

stakeholders to request up to seven 

minutes to address the Board in-person 

during the meeting. The Board is 

interested in hearing from anyone 

involved in, or who represents, a 

relevant biomedical, biodefense, or 

health security industry; serves as 

faculty or conducts research at an 

academic institution; occupies a 

relevant health profession or works for 

a hospital system or health care 

consumer organization; or who serves in 

a relevant state, Tribal, territorial, or 

local government agency. Requests to 

provide remarks to the NBSB during the 

public meeting must be sent to NBSB@

hhs.gov by March 1, 2022. In that 

request, please provide the speaker’s 

name, title, and position, with a brief 

description of the topic that they will 

address. The number of speakers and 

topics will be based on relevance to the 

mission of the NBSB and amount of 

time available on the agenda. The 

charter of the NBSB may be reviewed on 

the ASPR/NBSB website. Topics and 

presentations with an obvious 

commercial bias, to include any form of 

advertising, marketing, or solicitation, 

will not be accepted. 

FOR FURTHER INFORMATION CONTACT: 

CAPT Christopher L. Perdue, MD, MPH, 

NBSB Designated Federal Official, 

Washington, DC, NBSB@hhs.gov. 

Dawn O’Connell, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 2022–01764 Filed 1–27–22; 8:45 am] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2022–1 Phase I: Adjuvant Development for 

Vaccines and for Autoimmune and Allergic 

Diseases (Topic 105). 

Date: February 18, 2022. 

Time: 10:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G51, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Thomas F. Conway, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G51, Rockville, MD 

20852, 240–507–9685, thomas.conway@

nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2022–1 Phase II: Adjuvant Development for 

Vaccines and for Autoimmune and Allergic 

Diseases (Topic 105). 

Date: February 18, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G51, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Thomas F. Conway, Ph.D., 

Scientific Review Officer, Scientific Review, 

Program Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G51, Rockville, MD 

20852, 240–507–9685, thomas.conway@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 25, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–01746 Filed 1–27–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; NIGMS Review of SuRE First 

Applications. 

Date: March 22, 2022. 

Time: 10:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 45 Center Drive, Bethesda, 

MD 20892 (Video Meeting). 

Contact Person: Tracy Koretsky, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 45 

Center Drive, MSC 6200, Room 3AN.12F, 

Bethesda, MD 20892, 301 594 2886, 

tracy.koretsky@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.859, Biomedical Research and 

Research Training, National Institutes of 

Health, HHS) 

Dated: January 24, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–01741 Filed 1–27–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

UE5: Research Education Course in Product 


jspears on DSK121TN23PROD with NOTICES1